Amgen will pay $50 million upfront to fund the five programs, with a potential transaction value of $1.9 billion plus future royalties, according to a Jan. 6 press release.
For each program, Amgen will pay up to $370 million in future milestones and royalties. It will also participate in a future financing round for Generate.
Cambridge, Mass.-based Generate Biomedicines is a company that uses machine learning and AI to program protein therapeutics.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
